Several members of the growing TNF superfamily can regulate the elimination of immune cells by inducing apoptosis (1). TRAIL (TNF-related apoptosis-inducing ligand) or APO-2L is a member of the TNF superfamily that induces apoptosis by activating the death receptors DR4 and DR5 (2,3). TRAIL is attracting great interesting as an anti-cancer agent because it can induce apoptosis in a broad range of tumor cells, but only rarely in non-transformed cells, and independently of p53 status (2&4). For a time it was a it was unclear how TRAIL could induce apoptosis in tumor cells but not in non-transformed cells, while both of the cell types expressed the DR4 and DR5 death receptors. The discovery that DcR1 or TRID are mostly expressed on normal cells but not in most cancer cell lines helped to solve the puzzle, because these proteins act as decoys for the TRAIL protein (5).
For Western Blotting, use at a dilution of 1:200 Optimal dilutions should be determined by the user.
Type: Primary
Antigen: TNF-related Apoptosis-inducing Ligand
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope:
Host: Rabbit
Isotype: IgG
Reactivity: Human